Compare CAE & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAE | PRAX |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.6B |
| IPO Year | 2002 | 2020 |
| Metric | CAE | PRAX |
|---|---|---|
| Price | $29.92 | $319.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $34.33 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 724.3K | 364.5K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.95 | N/A |
| Revenue Next Year | $2.93 | $6,395.88 |
| P/E Ratio | $35.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.36 | $26.70 |
| 52 Week High | $34.24 | $354.87 |
| Indicator | CAE | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 52.94 |
| Support Level | $28.38 | $290.36 |
| Resistance Level | $29.71 | N/A |
| Average True Range (ATR) | 0.98 | 17.96 |
| MACD | -0.04 | -2.64 |
| Stochastic Oscillator | 27.04 | 55.32 |
CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: Civil Aviation which offers comprehensive training solutions for flight, cabin, maintenance, and ground personnel in commercial, business, and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training, and crew sourcing services, as well as aircraft flight operations solutions; and Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.